SYDNEY, April 6 /PRNewswire-Asia/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced the appointment of the U.S. life science investment manager Richard van den Broek to its Board of Directors.
Mr van den Broek is founder and managing partner of HSMR Advisors LLC, a U.S. based fund manager with an investment emphasis on small and mid-cap biotech public companies. HSMR Advisors has held a position on the Pharmaxis share register since 2005.
During his career Mr van den Broek has worked on both the buy and sell side of the funds management industry holding senior positions at Cooper Hill Partners, Hambrecht & Quist (H&Q), Merrill Lynch and Oppenheimer & Co.
"Richard has been an engaged investor for a number of years and has great insight into the life science industry and the U.S. capital markets," said Pharmaxis Chief Executive Officer, Dr Alan Robertson. "Our shareholders will benefit from his skills and experience."
In accepting the board position Mr van den Broek said: "Pharmaxis holds enormous promise and I look forward to being part of an exciting company at a key point in its development as a global provider of innovative medicines.
I am very much looking forward to working with the Pharmaxis Board."
Mr van den Broek is a Chartered Financial Analyst, and is a graduate of
For information on all Pharmaxis Board members, go to: http://www.pharmaxis.com.au/about-us/our-people/our-people_home.cfm
The statements contained in this media release that are not purely
historical are forward-looking statements within the meaning o
|SOURCE Pharmaxis Ltd|
Copyright©2009 PR Newswire.
All rights reserved